Lior Carmon

MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope

Khaled El‐Shami, Boaz Tirosh, Erez Bar‐Haim et al. · European Journal of Immunology · 1999 · 84 citations

Life Sciences, Immunology, Oncology +17

Phase I/<scp>II</scp> study exploring ImMucin, a pan‐major histocompatibility complex, anti‐<scp>MUC</scp>1 signal peptide vaccine, in multiple myeloma patients

Lior Carmon, Irit Avivi, Riva Kovjazin et al. · British Journal of Haematology · 2014 · 56 citations · Full text

Medicine, Immunology, Oncology +16

Signal peptides and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: Implications for vaccine development

Riva Kovjazin, Ilan Volovitz, Yair Daon et al. · Molecular Immunology · 2011 · 51 citations

Life Sciences, Immunology, Immunization +15

ImMucin: A novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors

Riva Kovjazin, Ilan Volovitz, Yulia Kundel et al. · Vaccine · 2011 · 42 citations

Medicine, Immunology, Oncology +14

Novel breast-tumor-associated MUC1-derived peptides: Characterization in Db−/− × β2 microglobulin (β2m) null mice transgenic for a chimeric HLA-A2.1/Db-β2 microglobulin single chain

Lior Carmon, Khaled El‐Shami, Adrian Paz et al. · International Journal of Cancer · 2000 · 40 citations · Full text

Life Sciences, Immunology, Oncology +17